Skip to content

Aclidinium bromide

Tudorza Pressair, Bretaris Genuair, Eklira Genuair (aclidinium bromide) is a small molecule pharmaceutical. Aclidinium bromide was first approved as Tudorza pressair on 2012-07-20. It is used to treat bronchial spasm and chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M1. Bretaris genuair, eklira genuair's patents are valid until 2029-03-13 (FDA).
Trade Name Bretaris Genuair, Eklira Genuair
Common Name Aclidinium bromide
Indication bronchial spasm, chronic obstructive pulmonary disease
Drug Class Quaternary ammonium derivatives: muscarinic receptor antagonists
Aclidinium bromide
Get full access now